Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

A. J. Collins, C. D. Bloomfield, B. A. Peterson, R. W. McKenna, J. R. Edson

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27+ months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.

Original languageEnglish (US)
Pages (from-to)1677-1680
Number of pages4
JournalArchives of Internal Medicine
Volume138
Issue number11
DOIs
StatePublished - 1978

Bibliographical note

Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, U.S. Gov't, P.H.S.

Fingerprint Dive into the research topics of 'Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction'. Together they form a unique fingerprint.

Cite this